New HIV study offers patients a choice: daily pill or bimonthly shot
NCT ID NCT05917509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at two ways to control HIV in 171 adults who had never been treated before. Everyone started with a daily pill (dolutegravir/lamivudine). Once the virus was undetectable, participants could choose to switch to a shot (cabotegravir plus rilpivirine) given every two months or stay on the pill. The goal was to see how well each option kept the virus suppressed and how patients felt about their treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Birmingham, Alabama, 35205, United States
-
GSK Investigational Site
Bakersfield, California, 93301, United States
-
GSK Investigational Site
Fort Lauderdale, Florida, 33308, United States
-
GSK Investigational Site
Ft. Pierce, Florida, 34982, United States
-
GSK Investigational Site
Orlando, Florida, 32804, United States
-
GSK Investigational Site
Pensacola, Florida, 32504, United States
-
GSK Investigational Site
Berkley, Michigan, 48072, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
Omaha, Nebraska, 68198, United States
-
GSK Investigational Site
Henderson, Nevada, 89106, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Huntersville, North Carolina, 28078, United States
-
GSK Investigational Site
Beaumont, Texas, 77701, United States
-
GSK Investigational Site
Dallas, Texas, 75246, United States
-
GSK Investigational Site
Fort Worth, Texas, 76104, United States
-
GSK Investigational Site
Buenos Aires, C1202, Argentina
-
GSK Investigational Site
Ciudad Autonoma de Bueno, 1405, Argentina
-
GSK Investigational Site
Mar del Plata, B7600DHK, Argentina
-
GSK Investigational Site
Rosario, S2013, Argentina
-
GSK Investigational Site
Hamilton, Ontario, L8S 1A4, Canada
-
GSK Investigational Site
Montreal, Quebec, H2L 4P9, Canada
-
GSK Investigational Site
La Cisterna, 7970000, Chile
-
GSK Investigational Site
Providencia, 7500000, Chile
-
GSK Investigational Site
Santiago, 9500000, Chile
-
GSK Investigational Site
Temuco, 4780000, Chile
-
GSK Investigational Site
Créteil, 94000, France
-
GSK Investigational Site
Orléans, 45067, France
-
GSK Investigational Site
Paris, 75004, France
-
GSK Investigational Site
Paris, 75015, France
-
GSK Investigational Site
Paris, 75475, France
-
GSK Investigational Site
Düsseldorf, 40225, Germany
-
GSK Investigational Site
Frankfurt am Main, 60329, Germany
-
GSK Investigational Site
Hamburg, 20246, Germany
-
GSK Investigational Site
München, 80337, Germany
-
GSK Investigational Site
Foggia, 71100, Italy
-
GSK Investigational Site
Milan, 20127, Italy
-
GSK Investigational Site
Milan, 20157, Italy
-
GSK Investigational Site
Roma, 00149, Italy
-
GSK Investigational Site
Ponce, 00717-1563, Puerto Rico
-
GSK Investigational Site
Almería, 04009, Spain
-
GSK Investigational Site
Granada, 35016, Spain
-
GSK Investigational Site
La Laguna-Tenerife, 35010, Spain
-
GSK Investigational Site
Madrid, 28007, Spain
-
GSK Investigational Site
Madrid, 28031, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
-
GSK Investigational Site
Murcia, 30008, Spain
-
GSK Investigational Site
Seville, 41071, Spain